These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Successful treatment of progressive dialysis encephalopathy. Case report]. Weiland P; Köhler M; Glatzel E Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157 [TBL] [Abstract][Full Text] [Related]
8. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Milne FJ; Sharf B; Bell P; Meyers AM Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027 [TBL] [Abstract][Full Text] [Related]
12. Aluminum and iron overload in chronic dialysis. Ackrill P; Day JP; Ahmed R Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407 [No Abstract] [Full Text] [Related]
13. Role of desferrioxamine in the treatment of dialysis encephalopathy. Ackrill P; Ralston AJ; Day JP Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985 [No Abstract] [Full Text] [Related]
17. Aluminium overload influences cognitive function in patients on dialysis. Kambova L; Ionova D; Kirijakov Z Nephrol Dial Transplant; 1994; 9(9):1357. PubMed ID: 7816312 [No Abstract] [Full Text] [Related]
18. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease. Marumo F; Umetani N; Sato N; Takahashi Y J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745 [No Abstract] [Full Text] [Related]
19. Desferrioxamine in the treatment of aluminum overload. Ackrill P; Day JP Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106 [TBL] [Abstract][Full Text] [Related]
20. Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine. Brown SJ; Slizofski WJ; Dadparvar S J Nucl Med; 1990 Jan; 31(1):115-7. PubMed ID: 2295931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]